Depreciation, Depletion and Amortization of Ernexa Therapeutics Inc. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit: us-gaap: USD
Description: The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Summary: Ernexa Therapeutics Inc. annual and quarterly Depreciation, Depletion and Amortization in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
Ernexa Therapeutics Inc. Depreciation, Depletion and Amortization for the quarter ending 31 Mar 2025 was $18,000, a 54% decline year-over-year.
Ernexa Therapeutics Inc. annual Depreciation, Depletion and Amortization for 2025 was $65,000, a 53% decline from 2024.
Ernexa Therapeutics Inc. annual Depreciation, Depletion and Amortization for 2024 was $139,000, a 65% increase from 2023.
Ernexa Therapeutics Inc. annual Depreciation, Depletion and Amortization for 2023 was $84,000, a 48% decline from 2022.
Source SEC data: View on sec.gov

Depreciation, Depletion and Amortization, Annual (USD)

Depreciation, Depletion and Amortization, YoY Annual Change (%)

Depreciation, Depletion and Amortization, Quarterly (USD)

Depreciation, Depletion and Amortization, YoY Quarterly Change (%)

Ernexa Therapeutics Inc. Annual Depreciation, Depletion and Amortization (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2025	$65,000	-$74,000	-53%	01 Jan 2025	31 Dec 2025	10-K	13 Mar 2026	2025	FY
2024	$139,000	+$55,000	+65%	01 Jan 2024	31 Dec 2024	10-K	13 Mar 2026	2025	FY
2023	$84,000	-$77,000	-48%	01 Jan 2023	31 Dec 2023	10-K	12 Mar 2025	2024	FY
2022	$161,000	+$44,000	+38%	01 Jan 2022	31 Dec 2022	10-K	14 Mar 2024	2023	FY
2021	$117,000	+$19,000	+19%	01 Jan 2021	31 Dec 2021	10-K	20 Mar 2023	2022	FY
2020	$98,000	-$2,779,000	-97%	01 Jan 2020	31 Dec 2020	10-K/A	01 Jul 2022	2021	FY
2019	$2,877,000	+$113,000	+4.1%	01 Jan 2019	31 Dec 2019	10-K	19 Mar 2020	2019	FY
2018	$2,764,000	+$447,000	+19%	01 Jan 2018	31 Dec 2018	10-K	19 Mar 2020	2019	FY
2017	$2,317,000	-$570,000	-20%	01 Jan 2017	31 Dec 2017	10-K	22 Mar 2019	2018	FY
2016	$2,887,000	-$217,000	-7%	01 Jan 2016	31 Dec 2016	10-K	09 Mar 2018	2017	FY
2015	$3,104,000	+$359,000	+13%	01 Jan 2015	31 Dec 2015	10-K	09 Mar 2017	2016	FY
2014	$2,745,000	-$104,000	-3.6%	01 Jan 2014	31 Dec 2014	10-K	15 Mar 2016	2015	FY
2013	$2,849,000	-$30,000	-1%	01 Jan 2013	31 Dec 2013	10-K	27 Mar 2015	2014	FY
2012	$2,879,000	-$381,000	-12%	01 Jan 2012	31 Dec 2012	10-K	31 Mar 2014	2013	FY
2011	$3,260,000	+$57,000	+1.8%	01 Jan 2011	31 Dec 2011	10-K	29 Mar 2013	2012	FY
2010	$3,203,000			01 Jan 2010	31 Dec 2010	10-K	30 Mar 2012	2011	FY

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2025	$18,000	-$21,000	-54%	01 Jan 2025	31 Mar 2025	10-Q	07 May 2025	2025	Q1
Q1 2024	$39,000	+$18,000	+86%	01 Jan 2024	31 Mar 2024	10-Q	07 May 2025	2025	Q1
Q1 2023	$21,000	-$15,000	-42%	01 Jan 2023	31 Mar 2023	10-Q	14 May 2024	2024	Q1
Q1 2022	$36,000	+$11,000	+44%	01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1
Q1 2021	$25,000	+$2,001	+8.7%	01 Jan 2021	31 Mar 2021	10-Q	01 Jul 2022	2022	Q1
Q1 2020	$22,999	-$724,001	-97%	01 Jan 2020	31 Mar 2020	10-Q	17 May 2021	2021	Q1
Q1 2019	$747,000	+$108,000	+17%	01 Jan 2019	31 Mar 2019	10-Q	20 May 2020	2020	Q1
Q1 2018	$639,000	+$60,000	+10%	01 Jan 2018	31 Mar 2018	10-Q	14 May 2019	2019	Q1
Q1 2017	$579,000	-$178,000	-24%	01 Jan 2017	31 Mar 2017	10-Q	11 May 2018	2018	Q1
Q1 2016	$757,000	+$56,000	+8%	01 Jan 2016	31 Mar 2016	10-Q	04 May 2017	2017	Q1
Q1 2015	$701,000	+$16,000	+2.3%	01 Jan 2015	31 Mar 2015	10-Q	09 May 2016	2016	Q1
Q1 2014	$685,000	-$104,000	-13%	01 Jan 2014	31 Mar 2014	10-Q	08 May 2015	2015	Q1
Q1 2013	$789,000	+$66,000	+9.1%	01 Jan 2013	31 Mar 2013	10-Q	15 May 2014	2014	Q1
Q1 2012	$723,000	-$90,000	-11%	01 Jan 2012	31 Mar 2012	10-Q	13 May 2013	2013	Q1
Q1 2011	$813,000			01 Jan 2011	31 Mar 2011	10-Q	11 May 2012	2012	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.